C

City Therapeutics

Develops RNAi therapeutics using trigger molecules

Senior Director - Clinical Development, Medical Director

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • An MD or equivalent medical degree is required.
  • A minimum of 6 years of relevant clinical development experience within the biotechnology or pharmaceutical industry is required.
  • Experience serving as a medical monitor and providing medical leadership for clinical trials is required.
  • Demonstrated experience designing and executing early-stage clinical studies is required.
  • A strong understanding of clinical trial design, drug development, Good Clinical Practice, and global regulatory requirements is required.
  • Experience contributing to regulatory submissions and participating in interactions with health authorities is required.
  • Ability to analyze and communicate complex clinical and scientific information clearly and effectively is required.
  • Experience working within cross-functional development teams and influencing decisions collaboratively is required.
  • Ability to operate effectively in a fast-paced, growing biotechnology company and balance strategic thinking with hands-on execution is required.
  • Board certification or board eligibility in a relevant medical specialty is strongly preferred but not required.
  • Experience supporting programs through later-stage development is highly desirable.

Responsibilities

  • Provide medical and scientific leadership for one or more clinical development programs.
  • Develop and execute clinical development plans aligned with overall program and corporate objectives.
  • Lead the design and development of clinical development plans and study protocols, including study objectives, endpoints, eligibility criteria, dose-escalation strategies, and safety-monitoring plans.
  • Serve as the medical monitor for assigned clinical trials and provide ongoing oversight of participant safety, medical data, and emerging benefit-risk profiles.
  • Partner with Clinical Operations to support high-quality and timely study execution.
  • Review and interpret clinical safety, efficacy, pharmacokinetic, pharmacodynamic, and biomarker data.
  • Lead or contribute to clinical study reports, investigator brochures, regulatory submissions, informed consent documents, and other clinical and regulatory materials.
  • Present clinical strategy and program updates to executive leadership, governance committees, investigators, and external partners.
  • Support interactions with global health authorities, including the FDA and other regulatory agencies.
  • Build relationships with investigators, key opinion leaders, clinical research organizations, and other external partners.
  • Collaborate with Biometrics to develop statistical analysis plans and ensure the quality and integrity of clinical data.
  • Contribute medical expertise to translational, nonclinical, regulatory, and commercial planning.
  • Identify clinical risks and recommend practical solutions to keep programs moving forward.
  • Monitor developments in the therapeutic landscape and incorporate relevant scientific, medical, and competitive insights into clinical strategy.
  • Support due diligence, business development, and external collaboration activities as needed.
  • Mentor and develop clinical team members and contribute to the continued growth of the Clinical Development function.
  • Foster a culture reflecting the company’s values of Courage, Innovation, Tempo, and Yes.

Desired Qualifications

  • Experience in RNA therapeutics, rare diseases, ophthalmology, immunology, neurology, or another relevant therapeutic area is preferred but not required.

About the Company

City Therapeutics

Develops RNAi therapeutics using trigger molecules

City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at City Therapeutics

See more jobs